Clinical trials: MACULAR EDEMA
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- GOBI (NCT07842016)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema (DME)
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18…
- Trial name
- CONGO (NCT04697758)
- Testing
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- AsclepiX Therapeutics, Inc.
Retinal Vein Occlusion, Macular Edema
Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex®) compared to ranibizumab (Lucentis®) in patients with branch retinal vein occlusion (BRVO).
- Trial name
- NCT01427751
- Testing
- dexamethasone intravitreal implant, ranibizumab
- Where
- 6 sites in France, Germany and 4 more
- Volunteers
- 307 people
- Sponsor
- Allergan
Macular Edema
A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
This was a Phase IV multicenter, randomized, open-label study, with masking of the vision examiner, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein…
- Trial name
- NCT01277302
- Testing
- Ranibizumab
- Where
- 42 sites in United States
- Volunteers
- 202 people
- Sponsor
- Genentech, Inc.
Diabetic Macular Edema
Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection
To assess the biomarker profile in diabetic macular edema patients in response to intravitreal aflibercept injection. Patients with diabetic macular edema who meet study requirements will receive monthly intravitreal injections…
- Trial name
- NCT03297684
- Testing
- Aflibercept Injection [Eylea]
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Advanced Eye Research Associates
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD)
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
This Phase 4, multicenter, randomized, double-masked clinical study evaluates the efficacy and safety of chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO) compared with routine anesthesia (topical proparacaine 0.5% combined…
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Trial name
- Quell (NCT07456826)
- Testing
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Harrow Inc
Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO
A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema
This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema
- Trial name
- NCT07844343
- Testing
- SB15 PFS
- Where
- 3 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Diabetic Macular Edema
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation at various doses in patients with diabetic macular edema.
- Trial name
- NCT00656643
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Santen Inc.
Diabetic Macular Edema
A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of diabetic macular edema.
- Trial name
- NCT00168337
- Testing
- Dexamethasone
- Where
- 14 sites in United States, Brazil and 12 more
- Volunteers
- 554 people
- Sponsor
- Allergan
Macular Edema, Macular Degeneration
Study Evaluating Retinal Health Monitoring System Thickness Module
Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).
- Trial name
- NCT04428242
- Testing
- RHMS-RTM, SD-OCT
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
DME, Diabetic Macular Edema
Study of CU06-1004 in Patients With Daibetic Macular Edema
This phase 2b trial is a randomized, double-masked, parallel-group, multi-center study in approximately 156 patients with Diabetic Macular Edema to evaluate the efficacy and safety of CU06-1004 orally administered once daily for…
- Conditions
- DME, Diabetic Macular Edema, Diabetic Macular Edema (DME)
- Trial name
- NCT07459829
- Testing
- CU06-1004
- Volunteers
- 156 people
- Sponsor
- Curacle Co., Ltd.
Diabetic Macular Edema
First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers
This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.
- Trial name
- NCT04795037
- Testing
- CU06-1004, Single dose, CU06-1004, Multiple doses
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Curacle Co., Ltd.
Diabetic Macular Edema
The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)
This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 12 weeks.
- Trial name
- NCT05573100
- Testing
- CU06-1004
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 67 people
- Sponsor
- Curacle Co., Ltd.
Center Involved Diabetic Macular Edema, Diabetic Macular Edema
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema
- Trial name
- DME (NCT05802329)
- Testing
- OCU200
- Where
- 5 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ocugen
Diabetic Macular Edema
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema
This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI) to participants who…
- Trial name
- Rhone-X (NCT04432831)
- Testing
- Faricimab
- Where
- 320 sites in United States, Argentina and 28 more
- Volunteers
- 1,479 people
- Sponsor
- Hoffmann-La Roche
Diabetic Retinopathy
Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
The purpose of this study was to demonstrate that the change of best corrected visual acuity (BCVA) was comparable in patients treated with ranibizumab at the discretion of the investigator vs.
- Trial name
- DIVERSE (NCT02366468)
- Testing
- ranibizumab 0.5 mg
- Where
- 30 sites in Germany
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Oedema, Retinal Vein Occlusion with Macular Oedema
Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy
This trial is a phase II, multi-center, single-masked (assessors) dose-ranging study designed to evaluate the comparative safety and preliminary efficacy of two dosage regimens of the IBE-814 IVT Dexamethasone Implant in patients…
- Trial name
- NCT04576689
- Testing
- IBE-814 70ug, IBE-814 140ug
- Where
- 21 sites in Australia, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Ripple Therapeutics Pty Ltd
Diabetic Macular Edema
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema
A Phase 2 Multi center, Randomized, Controlled, Double-Masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate® (Alg-1001) As Compared To Avastin® In The Treatment Of Diabetic Macular Edema
- Trial name
- NCT02348918
- Testing
- Luminate 1.0mg, Luminate 2.0mg, Luminate 3.0mg
- Where
- 17 sites in United States
- Volunteers
- 218 people
- Sponsor
- Allegro Ophthalmics, LLC
Diabetic Retinopathy, Diabetic Eye Problems
Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
The duration of diabetes is directly related to eye complications. Diabetic retinopathy affects 80 percent of those who have had diabetes for 20 years or more.
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT04805541
- Testing
- Color Fundus Photography, Mydriatic Agent, EyeCheckup - AI Based DR Screening
- Where
- Turkey (Türkiye)
- Volunteers
- 900 people
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Diabetic Macular Edema (DME)
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema…
- Trial name
- BAROLO (NCT06957080)
- Testing
- Remigromig, Ranibizumab
- Where
- 164 sites in United States, Argentina and 4 more
- Volunteers
- 1,054 people
- Sponsor
- EyeBiotech Ltd.